OBJECTIVE  To explore risk factors of thrombopenia related to imipenem cilastatin sodium based on China Hospital Pharmacovigilance System(CHPS), to provide reference for safely clinical use of imipenem cilastatin sodium.

METHODS  An evaluation plan was constructed in CHPS to select inpatients treated with imipenem cilastatin sodium in Xuchang Central Hospital Affiliated to Henan University of Science and Technology from Apr 1st, 2017 to Apr 1st, 2022. According to whether thrombopenia had happened, patients were divided into thrombopenia group and non-thrombopenia group. Clinical characteristics between the two groups were compared. The risk factors of thrombopenia related to imipenem cilastatin sodium were analyzed using the multivariable logistic regression model.

RESULTS  A total of 559 patients were enrolled into this study. Among them, 136 patients developed thrombopenia. The incidence of thrombopenia was 24.33%. Result of multivariate Logistic regression analysis showed that alkaline phosphatase, shock, bloodstream infection, admission to intensive care units, daily dose and treatment course were independent risk factors of thrombopenia related to imipenem cilastatin sodium.

CONCLUSION Imipenem cilastatin sodium can induce thrombopenia. Attentions should be paid to patients with risk factors mentioned above, and platelet count should be monitored when patients are treated with imipenem cilastatin sodium in order to take timely and proper diagnosis and treatment.